Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 3,909 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

NCT01324388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Metoprolol, Lisinopril, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 28, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 28, 2026, 6:19 AM EDT
Completed Phase 2 Interventional

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

NCT01896180
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
Interventions
ALZ-1101, Latanoprost
Drug
Lead sponsor
Alleanza Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 28, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Unmet Social Needs Study

NCT04977583
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Diabetes Mellitus, Hyperlipidemia
Interventions
Unmet Need Screening, Unmet Need Referral - Resource Sheet, Unmet Need Referral Assistance
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 28, 2026, 6:19 AM EDT
Recruiting Phase 4 Interventional

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

NCT06246396
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Minocycline Hydrochloride, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Outcomes in Cataract Surgery With OMNI Canaloplasty vs Cataract Surgery With OMNI Canaloplasty and Hydrus Stent

NCT05949242
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI canaloplasty, Hydrus microstent
Device
Lead sponsor
Ridge Eye Care
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
4
States / cities
Marysville, California • Oroville, California • Paradise, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 28, 2026, 6:19 AM EDT
Not yet recruiting Not applicable Interventional

Beta-2 Adrenergic Receptor Polymorphic Variants: An Endotype of Salt Sensitive Hypertension (Beta2AR).

NCT07832942
View directory record Official record
Conditions
Genetics in Hypertension
Interventions
low sodium diet, high sodium diet, renal plasma flow, SIEA collection
Other · Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional Results available

DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study

NCT01321073
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Model 10642 Implantable Intravascular Catheter
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Terminated Not applicable Interventional Results available

Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD

NCT02975505
View directory record Official record
Conditions
Chronic Kidney Disease, Bloodpressure, Hypertension
Interventions
Strict blood pressure control
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 28, 2026, 6:19 AM EDT
Completed No phase listed Observational

Real-world Aliskiren Use in Diabetic Patients

NCT01393860
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 28, 2026, 6:19 AM EDT
Recruiting Phase 2 Interventional

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

NCT07543120
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
QCZ484
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
19
States / cities
Garden Grove, California • Los Angeles, California • Brandon, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 28, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional

Reducing Cardiovascular Risks: The Role of Alcohol Use

NCT07783061
View directory record Official record
Conditions
Alcohol Drinking, Drinking Behavior, At-risk Drinking, Cardiovascular Risk Factor, High Blood Pressure
Interventions
Alcohol Abstinence, Control arm
Behavioral · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
26 Years to 49 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 28, 2026, 6:19 AM EDT
Recruiting Phase 3 Interventional

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723
View directory record Official record
Conditions
Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozin, Placebo/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
133
States / cities
Fairhope, Alabama • Surprise, Arizona • Tucson, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Blood Pressure

NCT01496469
View directory record Official record
Conditions
Hypertension
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Foley, Alabama • Buena Park, California • Carmichael, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 28, 2026, 6:19 AM EDT
Completed No phase listed Observational

Microbial Metabolites and Outcomes of Pregnancy Study

NCT06362356
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension

NCT05121337
View directory record Official record
Conditions
Elevated Blood Pressure, Hypertension
Interventions
Dietitian-Assisted DASH groceries, Self-directed shopping
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

NCT02047656
View directory record Official record
Conditions
Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions
LFF269, Placebo to LFF269
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 28, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional Results available

Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide

NCT03298802
View directory record Official record
Conditions
Pre-Eclampsia, Gestational Hypertension, Superimposed Pre-Eclampsia, Hypertension, Pregnancy-Induced, Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia
Interventions
Hydrochlorothiazide 50mg Tablet, Placebo Tablet
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Austin, Texas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 6:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Response of Human Small Blood Vessels

NCT00001622
View directory record Official record
Conditions
Healthy, Hypercholesterolemia, Hypertension
Interventions
investigate the relationship between in vivo and in vitro vascular responses
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 6:19 AM EDT
Withdrawn Not applicable Interventional

Effect of Negative Pressure on Pattern Electroretinography Readings

NCT04433702
View directory record Official record
Conditions
Glaucoma, Open Angle, Low Risk, Ocular Hypertension, Glaucoma Suspect
Interventions
Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle, Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 28, 2026, 6:19 AM EDT
Terminated Not applicable Interventional

FSU Hypertension Self-Care Training Study

NCT01770756
View directory record Official record
Conditions
Hypertension
Interventions
Self-Care Training
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
25 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 28, 2026, 6:19 AM EDT